Melanoma antigen recognized by T-cells 1

DB15081Investigational

Melanoma antigen recognized by T-cells 1 is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery).

Mechanism: Pharmacologically active on Melanoma antigen recognized by T-cells 1
Curator reviewed
Also known as: ANTIGEN LB39-AA · ANTIGEN SK29-AA · MART1

Resolves to

Compound

UNIIC1357NAP5J

Targets

Q16655MLANA

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Melanoma antigen recognized by T-cells 1, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account